TherapeuticsMD (NASDAQ:TXMD) Posts Earnings Results, Beats Estimates By $6.13 EPS

TherapeuticsMD (NASDAQ:TXMD) issued its quarterly earnings data on Tuesday. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13, FiscalAI reports. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.The company had revenue of $0.87 million for the quarter, compared to the consensus estimate of $19.77 million.

TherapeuticsMD Price Performance

Shares of TXMD remained flat at $2.07 during mid-day trading on Tuesday. The stock had a trading volume of 14,514 shares, compared to its average volume of 50,151. TherapeuticsMD has a 1 year low of $0.99 and a 1 year high of $2.95. The company has a 50-day moving average price of $2.04 and a 200 day moving average price of $2.14. The firm has a market capitalization of $23.95 million, a PE ratio of 34.50 and a beta of 0.61.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its position in TherapeuticsMD stock. Renaissance Technologies LLC raised its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 171.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 96,500 shares of the company’s stock after buying an additional 61,000 shares during the period. Renaissance Technologies LLC owned about 0.83% of TherapeuticsMD worth $157,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of TherapeuticsMD in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, TherapeuticsMD presently has a consensus rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.